MedTrace Logo

Study of Psilocybin for Anorexia in Young Adults

NCT06399263 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-03-03

No results posted yet for this study

Summary

This is a single site trial of psilocybin therapy for the treatment of refractory Anorexia Nervosa in young adults. The psilocybin therapy will include three preparatory sessions, psilocybin dosing session one (20mg), two integration sessions, psilocybin dosing session two (up to 25mg), and three final integration sessions. Eating disorder symptoms will be measured pre and post treatment. One to two family member(s) of each young adult participant will be enrolled in the study. One of which will be required to attend a portion of two preparatory sessions and a portion of two integration sessions and receive psychoeducation about supporting the young adult participant through preparation and integration for psilocybin therapy. Investigators hypothesize that psilocybin will increase cognitive flexibility and that this increase will predict long-term changes in cognitive rigidity, habitual eating, and exercise behaviors in patients with Anorexia Nervosa.

Conditions

  • Anorexia Nervosa

Interventions

DRUG

Psilocybin

The psilocybin will include two dose administration sessions, first a 20mg administration, and second an administration of up to 25mg.

BEHAVIORAL

Preparation and Integration Sessions

The psilocybin therapy will include three preparatory sessions, two dose A integration sessions, and four final integration sessions.

Sponsors & Collaborators

  • Marissa Raymond-Flesch, MD, MPH

    lead OTHER

Principal Investigators

  • Marissa Raymond-Flesch, MD · University of California, San Francisco

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-18
Primary Completion
2029-11-30
Completion
2029-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06399263 on ClinicalTrials.gov